NO20076387L - Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer - Google Patents

Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer

Info

Publication number
NO20076387L
NO20076387L NO20076387A NO20076387A NO20076387L NO 20076387 L NO20076387 L NO 20076387L NO 20076387 A NO20076387 A NO 20076387A NO 20076387 A NO20076387 A NO 20076387A NO 20076387 L NO20076387 L NO 20076387L
Authority
NO
Norway
Prior art keywords
prevention
treatment
isoforms
inflammatory diseases
neurological inflammatory
Prior art date
Application number
NO20076387A
Other languages
English (en)
Other versions
NO339540B1 (no
Inventor
Yolande Chvatchko
Yves Sagot
Anne Corbaz
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20076387L publication Critical patent/NO20076387L/no
Publication of NO339540B1 publication Critical patent/NO339540B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SAMMENDRAG Oppfinnelsen angår anvendelse av en IL- I 813P-isoforrn som ikke bindes til IL- I 8 eller en agonist derav, til behandling eller forhindring av en nevrologisk og/eller inflammatorisk sykdom. Foretrukne isoformer for anvendelse innenfor rammen av den foreliggende oppfinnelsen inkluderer IL- I 8BPb og IL- I 8BPd.
NO20076387A 2005-06-03 2007-12-11 Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer NO339540B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05104863 2005-06-03
US68805705P 2005-06-07 2005-06-07
PCT/EP2006/062864 WO2006128911A2 (en) 2005-06-03 2006-06-02 Use of il-18bp isoforms for the treatment and/or prevention of neurological inflammatory diseases

Publications (2)

Publication Number Publication Date
NO20076387L true NO20076387L (no) 2008-02-29
NO339540B1 NO339540B1 (no) 2016-12-27

Family

ID=35058651

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076387A NO339540B1 (no) 2005-06-03 2007-12-11 Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer

Country Status (17)

Country Link
US (1) US8128920B2 (no)
EP (1) EP1888100B1 (no)
JP (1) JP5048658B2 (no)
AT (1) ATE530227T1 (no)
AU (1) AU2006254106B2 (no)
CA (1) CA2610691C (no)
CY (1) CY1112128T1 (no)
DK (1) DK1888100T3 (no)
ES (1) ES2376534T3 (no)
HR (1) HRP20110788T1 (no)
IL (1) IL187839A (no)
NO (1) NO339540B1 (no)
PL (1) PL1888100T3 (no)
PT (1) PT1888100E (no)
RS (1) RS52192B (no)
SI (1) SI1888100T1 (no)
WO (1) WO2006128911A2 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105057A1 (en) * 1997-03-19 2003-06-05 Yale University Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
JP4216950B2 (ja) * 1998-09-01 2009-01-28 株式会社林原生物化学研究所 インターロイキン−１８結合蛋白質
CA2340579A1 (en) 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
KR20040030625A (ko) * 2001-05-25 2004-04-09 아레스 트레이딩 에스.에이. Ｃｎｓ 손상을 치료하거나 예방하기 위한 ｉｌ-18저해물질의 용도
JP5074030B2 (ja) 2003-05-13 2012-11-14 メルク セローノ ソシエテ アノニム Ｉｌ−１８結合タンパク質の活性変異体とその医学的応用

Also Published As

Publication number Publication date
CA2610691C (en) 2015-12-01
ES2376534T3 (es) 2012-03-14
HRP20110788T1 (hr) 2011-11-30
EP1888100B1 (en) 2011-10-26
NO339540B1 (no) 2016-12-27
CY1112128T1 (el) 2015-11-04
PL1888100T3 (pl) 2012-03-30
DK1888100T3 (da) 2012-01-23
US8128920B2 (en) 2012-03-06
IL187839A0 (en) 2008-03-20
JP5048658B2 (ja) 2012-10-17
US20080233085A1 (en) 2008-09-25
AU2006254106B2 (en) 2012-04-26
WO2006128911A2 (en) 2006-12-07
JP2008542340A (ja) 2008-11-27
WO2006128911A3 (en) 2007-03-29
SI1888100T1 (sl) 2012-01-31
AU2006254106A1 (en) 2006-12-07
RS52192B (en) 2012-10-31
CA2610691A1 (en) 2006-12-07
PT1888100E (pt) 2011-12-15
AU2006254106A8 (en) 2008-04-03
IL187839A (en) 2013-03-24
ATE530227T1 (de) 2011-11-15
EP1888100A2 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
NL301089I2 (nl) imlifidase
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
JP2009519986A5 (no)
TW200602330A (en) Compounds and compositions as PPAR modulators
NO20082699L (no) Immunoglobuliner
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
IL180979A (en) Isoindulin compounds and their use
ATE445624T1 (de) Verbindungen und zusammensetzungen als ppar- modulatoren
TW200611695A (en) Pyrrolopyridine derivatives
WO2007056366A3 (en) Compounds and compositions as ppar modulators
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
TW200745081A (en) Compounds
CY1113310T1 (el) Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων
EA200701867A1 (ru) Хинолиноновые соединения в качестве агонистов рецептора 5-ht
NO20076387L (no) Anvendelse av IL-18BP isoformer til behandling og/eller forhindring av neurologiske inflammatoriske sykdommer
TNSN06381A1 (en) Compounds and compositions as ppar modulators
TW200734335A (en) Compounds
WO2007022938A3 (en) Compounds
ATE397755T1 (de) Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten